Figure 6.
Effect of the peroxisome proliferator-activated receptor γ (PPARγ) ligand, 15d-PGJ2, on lipopolysaccharide (LPS, TLR4 ligand)- and peptidoglycan (PGN, TLR2 ligand)-induced NF-κB activation in cultured human biliary epithelial cells (BECs). BECs are pretreated in the presence or absence of 15d-PGJ2 (20 μM) before stimulation with LPS or peptidoglycan. Pretreatment with 15d-PGJ2 significantly prevents PAMP-induced NF-κB activation (* < .05).